Metabolic approaches to breast cancer treatment and prevention by Howell, Anthony
Standard systemic therapy for breast cancer treatment and
prevention are generally directed at reduction in cell growth
and increase in apoptosis by direct inhibition of DNA
synthesis or signalling pathways that control cell proliferation
and cell death. Data are accumulating that calorie restriction
(CR) and/or exercise, or agents that target metabolic path-
ways may have antitumour effects either alone or in combina-
tion with standard therapies for cancer prevention and
treatment, and merit further investigation. Here, we outline
evidence concerning the effectiveness of this approach.
The first observation, that energy restriction could retard
tumour growth, was reported nearly 100 years ago [1]. More
recently, Dirx and colleagues [2] conducted a meta-analysis
of 14 studies of the effect of calorie restriction on
spontaneous mammary tumour development in mice and
found that the pooled risk difference between mice given
restricted access and those given free access to food was
0.55 (95% confidence interval 0.41-0.69), irrespective of the
type of restricted nutrient. Whether CR affects human tumour
development is not clear. Epidemiological studies indicate
lower risk for breast cancer in women who have a period of
weight loss as compared with those who maintain or
continued to gain weight in mid-life [3,4]. Excess weight at
diagnosis and weight gain during breast cancer treatment
increases mortality from cancer and co-morbid conditions,
whereas diet modification reduces recurrence [5,6].
Although the data outlined above suggest that CR is effective
at preventing breast cancer and possibly inhibiting the growth
of overt tumours, currently it is unrealistic to expect CR to be
implemented on a population basis. This has led to studies on
whether intermittent CR is potentially more acceptable [7]
and investigation of pharmacological agents that might mimic
the effect of CR (calorie restriction mimetics [CRMs]) [8]. In
order to establish targets for CRM, it is important to gain an
understanding of the cellular and biochemical basis of CR.
Several animal studies have shown that CR inhibits cell
proliferation and stimulates apoptosis (for review, see [8]). The
experimental data are consistent with cell cycle arrest at the
G1/S transition and a shift into G0 with appropriate reductions
in cyclin kinases and increases in p21 and p27. Caspase
activity assays showed that caspase 9 and 3 are elevated in the
mammary tumours of CR rats, as compared with carcinomas
from fed animals given free access to food, which implies the
mitochondrial pathway of apoptosis is activated by CR [9].
Mechanistic studies on cell proliferation reduction and
apoptosis activation are highly important but they do not
indicate how a reduction in calories is translated into these
effects on mammary tumour cells. Reduction in the major
components of the diet (carbohydrate, lipids and proteins)
must affect tumour cell metabolism in some way, with
secondary results in alterations in cell cycle and cell death
pathways. It is of interest that Dirx and coworkers [2]
reported in their overview that CR was effective whatever the
component of diet was restricted. Thus, there may be more
than one metabolic pathway that mediates CR.
In general, breast tumour metabolic pathways appear to be
different compared with the normal cells from which they
arise. Warburg [10], in the 1920s, was the first to show that
glycolysis was markedly increased, and later Weinhouse and
colleagues [11] demonstrated that fatty acid synthesis was
also markedly increased in tumours. Warburg suggested that
high glycolytic rates in tumours were related to defects in
tumour mitochondria, and considerable support for this
hypothesis has recently accumulated [12].
An important advance in our understanding of how cells
sense their own energy status was the discovery of
adenosine monophosphate-related kinase (AMPK), which is
activated when cellular energy levels are reduced (low
AMP/ATP ratio) [13]. Activation of AMPK results in reduction
in cell synthetic (anabolic) pathways and increase in catabolic
pathways and oxidative phosphorylation (to generate ATP),
with associated reduction in cell proliferation. Some
metabolic pathways in tumours are shown in Figure 1.
Increased glycolysis and lipid synthesis may be thought of as
oncogenic and enzymes in the AMPK/tricarboxylic acid (TCA)
cycle pathway as tumour suppressors. Indeed, transfection of
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glycolytic enzymes into normal cells results in immortalization
[14], and mutations in components of the LKB1/AMPK
pathway result in tumour formation consistent with their
tumour suppression function (Figure 1).
The mechanism of action of some known CRMs is consistent
with the ‘oncogene’/tumour suppressor gene concept outlined
above. For example, inhibition of glycolysis in MCF7 cells with
2-deoxyglucose [15] or of fatty acid synthesis [16] with the
fatty acid and synthase inhibitor C93, or stimulation of AMPK
synthesis with the antidiabetic drug metformin [17] all inhibit
proliferation of human MCF7 cells in vitro. Also, enhancement
of TCA cycle activity is associated with inhibition of cell
growth. In tumours entry of pyruvate into the TCA cycle may
be reduced either by metabolism to lactate or inhibition of
pyruvate dehydrogenase by pyruvate dehydrogenase kinase
(PDK). Inhibition of lactate dehydrogenase activity by small
interfering RNA [18] or of PDK by 2-chloroacetate stimulates
mitochondrial activity [19] and is associated with inhibition of
tumour cell growth or direct stimulation of TCA cycle activity
using cell-permeating α-ketoglutarate [20].
The examples given above indicate that alteration in tumour
cell metabolism is a potential approach, either alone or in
addition to standard therapies for the prevention and
treatment of breast cancer.
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Figure 1
Simplified view of metabolic pathways in tumours. Enhanced pathways
are shown as thick lines. Potential inhibitors of glycolysis and lipid
synthesis and stimulators of the tricarboxylic acid (TCA) cycle are
shown. Calorie restriction would be expected to enhance adenosine
monophosphate-related kinase (AMPK) activity, which inhibits lipid
synthesis and generally stimulates TCA cycle activity.